Research programme: MKK-targeting molecules - Celgene
Alternative Names: MEK-targeting molecules research programme - Celgene; MKK-targeting molecules research programme - Celgene; Research programme: MEK-targeting molecules - CelgeneLatest Information Update: 04 Dec 2019
At a glance
- Originator Celgene Corporation
- Class
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 07 May 2007 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 02 Dec 2003 Preclinical trials in Inflammation in USA (unspecified route)